Eugene R Schiff MD

Clinical Trials

• Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials Start of enrollment: 2011 Sep 01

  Completed

  Phase 2

• HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network Start of enrollment: 2011 Nov 01

  Completed

• Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial Start of enrollment: 2012 Feb 07

  Completed

• Liver Fibrosis in Sickle Cell Disease Start of enrollment: 2012 Jul 01

  Completed

• Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant Start of enrollment: 2014 Mar 01

  Completed

  Phase 3

• A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection. Start of enrollment: 2014 Feb 01

  Completed

  Phase 3

• Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing Start of enrollment: 2014 Feb 01

  Completed

• Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay Start of enrollment: 2014 Mar 01

  Completed

• Rapid Diagnostics for HIV and Hepatitis Start of enrollment: 2014 May 01

  Withdrawn

  Not Applicable

• sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS Start of enrollment: 2014 Nov 14

  Completed

  Phase 1

• Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection Start of enrollment: 2014 Dec 09

  Terminated

• Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Start of enrollment: 2014 Dec 26

  Terminated

  Phase 4

• Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects Start of enrollment: 2015 Jan 12

  Completed

  Phase 1

• Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Start of enrollment: 2015 Sep 22

  TERMINATED

  PHASE3

• Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD Start of enrollment: 2016 Jan 01

  Terminated

  Phase 3

• Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) Start of enrollment: 2015 Dec 04

  Completed

  Phase 2

• Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis Start of enrollment: 2016 Jan 26

  Completed

  Phase 2

• Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2016 Mar 01

  Terminated

  Phase 3

• Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2016 Oct 24

  Terminated

  Phase 2

• Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis Start of enrollment: 2017 Feb 13

  Terminated

  Phase 3

• Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2017 Jan 30

  Terminated

  Phase 3

• Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis Start of enrollment: 2017 Feb 14

  Terminated

  Phase 2

• Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis Start of enrollment: 2017 Apr 06

  COMPLETED

  PHASE2

• Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis Start of enrollment: 2017 Jun 28

  Active, not recruiting

  Phase 2

• Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) Start of enrollment: 2017 Aug 22

  Completed

  Phase 2

• The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology Start of enrollment: 2017 Dec 08

  Terminated

  Phase 2

• Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Start of enrollment: 2017 Aug 30

  Completed

  Phase 3

• Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2018 Mar 21

  Completed

  Phase 2

• Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment Start of enrollment: 2018 Jun 22

  Terminated

  Phase 4

• Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a Start of enrollment: 2018 Dec 01

  Completed

  Phase 3

• Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2019 Jul 29

  Completed

  Phase 2

• Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis Start of enrollment: 2019 Aug 14

  Terminated

  Phase 2

• An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection Start of enrollment: 2018 Oct 11

  RECRUITING

  Roles: Principal Investigator, Contact

• Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein Start of enrollment: 2023 Mar 06

  RECRUITING

  PHASE3

  Roles: Principal Investigator

• Join now to see all